Enliven Therapeutics, Inc. (ELVN)Healthcare | Biotechnology | Boulder, United States | NasdaqGS
50.87 USD
-0.22
(-0.431%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 50.87 |
Hot Take ↕ | July 11, 2026, 6:49 a.m. EDT
The investment case for Enliven Therapeutics is currently broken by a severe disconnect between its valuation and its financial reality. Despite a 'strong buy' analyst consensus and a recent surge driven by clinical trial results, the company is burning cash aggressively with negative free cash flow and negative operating cash flow. The balance sheet, while technically liquid due to cash holdings, supports a business that is hemorrhaging money, and the stock has been decimated over the last five years, dropping nearly 78% from its peak. The recent price appreciation appears to be a speculative bubble fueled by the latest drug trial data rather than sustainable fundamentals, especially given the company was recently delisted from major indices like the Russell. The options market confirms this skepticism, with traders aggressively buying deep out-of-the-money puts to hedge against a potential crash if the hype fades or if further data disappoints. Until the company demonstrates a clear path to profitability or a definitive milestone that justifies the current premium, the risk-reward profile remains dangerously skewed toward permanent capital loss. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.110770 |
| AutoETS | 0.110771 |
| AutoTheta | 0.112321 |
| MSTL | 0.117995 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 3.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.501 |
| Excess Kurtosis | 0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.067 |
| Market Cap | 3,634,065,152 |
| Forward P/E | -21.88 |
| Beta | 0.26 |
| Website | https://www.enliventherapeutics.com |
As of July 11, 2026, 6:49 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes 17.5, 20, 25) expiring late 2026 and early 2027, which dwarfs call volume at those strikes. While there is some call activity at higher strikes (65) and new flow into 55-strike calls, the overwhelming capital deployment is in put writing or buying, suggesting a fear of a significant correction or a 'sell the news' event following the recent rally. Implied volatility is elevated on these protective puts, indicating the market prices in a high probability of a drop.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2213044 |
| Address1 | 6,200 Lookout Road |
| All Time High | 250.84 |
| All Time Low | 3.896 |
| Ask | 64.34 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,770,530 |
| Average Daily Volume3 Month | 1,335,990 |
| Average Volume | 1,335,990 |
| Average Volume10Days | 1,770,530 |
| Beta | 0.258 |
| Bid | 36.36 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 7.446 |
| City | Boulder |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 50.87 |
| Current Ratio | 40.318 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 51.025 |
| Day Low | 49.56 |
| Debt To Equity | 0.067 |
| Display Name | Enliven Therapeutics |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -115,585,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -22.893 |
| Enterprise Value | 2,646,135,552 |
| Eps Current Year | -1.695 |
| Eps Forward | -2.325 |
| Eps Trailing Twelve Months | -1.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 43.0862 |
| Fifty Day Average Change | 7.783798 |
| Fifty Day Average Change Percent | 0.1806564 |
| Fifty Two Week Change Percent | 122.13044 |
| Fifty Two Week High | 52.39 |
| Fifty Two Week High Change | -1.5200005 |
| Fifty Two Week High Change Percent | -0.02901318 |
| Fifty Two Week Low | 14.785 |
| Fifty Two Week Low Change | 36.085 |
| Fifty Two Week Low Change Percent | 2.4406493 |
| Fifty Two Week Range | 14.785 - 52.39 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,584,019,800,000 |
| Float Shares | 53,266,248 |
| Forward Eps | -2.325 |
| Forward P E | -21.879568 |
| Free Cashflow | -46,080,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 61 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06546 |
| Held Percent Institutions | 0.90143996 |
| Implied Shares Outstanding | 71,438,280 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado. |
| Long Name | Enliven Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,634,065,152 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_693128628 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -98,777,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,649,781,725 |
| Number Of Analyst Opinions | 9 |
| Open | 50.97 |
| Operating Cashflow | -65,465,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 720 647 8519 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 50.87 |
| Post Market Time | 1,783,981,117 |
| Previous Close | 51.09 |
| Price Eps Current Year | -30.011797 |
| Price Hint | 2 |
| Price To Book | 6.831856 |
| Profit Margins | 0.0 |
| Quick Ratio | 39.384 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.220001 |
| Regular Market Change Percent | -0.430615 |
| Regular Market Day High | 51.025 |
| Regular Market Day Low | 49.56 |
| Regular Market Day Range | 49.56 - 51.025 |
| Regular Market Open | 50.97 |
| Regular Market Previous Close | 51.09 |
| Regular Market Price | 50.87 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 585,835 |
| Return On Assets | -0.1886 |
| Return On Equity | -0.26637 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 71,438,280 |
| Shares Percent Shares Out | 0.119399995 |
| Shares Short | 8,527,025 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,213,383 |
| Short Name | Enliven Therapeutics, Inc. |
| Short Percent Of Float | 0.1739 |
| Short Ratio | 3.49 |
| Source Interval | 15 |
| State | CO |
| Symbol | ELVN |
| Target High Price | 80.0 |
| Target Low Price | 59.0 |
| Target Mean Price | 66.0 |
| Target Median Price | 62.0 |
| Total Cash | 452,400,992 |
| Total Cash Per Share | 7.428 |
| Total Debt | 302,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.3419 |
| Two Hundred Day Average Change | 20.5281 |
| Two Hundred Day Average Change Percent | 0.67655945 |
| Type Disp | Equity |
| Volume | 585,835 |
| Website | https://www.enliventherapeutics.com |
| Zip | 80,301 |